Editas Medicine, Inc. financial data

Symbol
EDIT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11 Hurley St., Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 4, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 436 % -32.2%
Debt-to-equity 57.2 % +40.2%
Return On Equity -80.1 % -47.7%
Return On Assets -51 % -32.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 82.5M shares +1.07%
Common Stock, Shares, Outstanding 82.5M shares +1.07%
Entity Public Float 671M USD +5.89%
Common Stock, Value, Issued 8K USD 0%
Weighted Average Number of Shares Outstanding, Basic 82.5M shares +1.03%
Weighted Average Number of Shares Outstanding, Diluted 82.5M shares +1.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 61.8M USD +151%
Research and Development Expense 220M USD +37.5%
General and Administrative Expense 70.1M USD -4.23%
Operating Income (Loss) -229M USD -9.52%
Nonoperating Income (Expense) 18M USD +32.2%
Net Income (Loss) Attributable to Parent -211M USD -7.94%
Earnings Per Share, Basic -2.53 USD/shares +6.3%
Earnings Per Share, Diluted -2.53 USD/shares +6.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 95.8M USD +16.1%
Marketable Securities, Current 169M USD -36.6%
Assets, Current 271M USD -24.4%
Property, Plant and Equipment, Net 15.4M USD +33.4%
Operating Lease, Right-of-Use Asset 35.7M USD +11.9%
Other Assets, Noncurrent 5.28M USD -8.24%
Assets 328M USD -35.1%
Accounts Payable, Current 12.5M USD +20%
Employee-related Liabilities, Current 11.9M USD +25.2%
Accrued Liabilities, Current 28.8M USD -4.93%
Contract with Customer, Liability, Current 14.7M USD +78.6%
Liabilities, Current 72.4M USD +23.5%
Contract with Customer, Liability, Noncurrent 54.2M USD -10.7%
Operating Lease, Liability, Noncurrent 22.1M USD -11.3%
Other Liabilities, Noncurrent 3.28M USD
Liabilities 152M USD +5.37%
Accumulated Other Comprehensive Income (Loss), Net of Tax 522K USD
Retained Earnings (Accumulated Deficit) -1.42B USD -17.4%
Stockholders' Equity Attributable to Parent 176M USD -51.3%
Liabilities and Equity 328M USD -35.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.9M USD -39.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -4.75M USD -120%
Common Stock, Shares Authorized 195M shares 0%
Common Stock, Shares, Issued 82.5M shares +1.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -54.4M USD -335%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 99.7M USD +15.4%
Deferred Tax Assets, Valuation Allowance 329M USD +11%
Deferred Tax Assets, Gross 338M USD +9.45%
Operating Lease, Liability 36.5M USD -16.9%
Depreciation 1.41M USD -8.74%
Payments to Acquire Property, Plant, and Equipment 1.87M USD +1.69%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -209M USD -8.51%
Lessee, Operating Lease, Liability, to be Paid 43.4M USD -19.6%
Property, Plant and Equipment, Gross 45.9M USD +25.7%
Operating Lease, Liability, Current 16.4M USD +69.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.39M USD -32.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 14.8M USD +2.02%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.91M USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.13M USD +0.08%
Deferred Tax Assets, Operating Loss Carryforwards 153M USD +5.88%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 13.7M USD +15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.08M USD +2.11%
Operating Lease, Payments 3.85M USD -1.28%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 9.19M USD -26.8%
Share-based Payment Arrangement, Expense 22.7M USD +14.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%